Research programme: siRNA and bionanotechnology therapies - ViRexx

Drug Profile

Research programme: siRNA and bionanotechnology therapies - ViRexx

Alternative Names: Bionanoparticles - ViRexx; siRNA - ViRexx

Latest Information Update: 06 Mar 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ViRexx Medical Corp
  • Developer Endo International; National Institute for Nanotechnology; Paladin Labs
  • Class Small interfering RNA
  • Mechanism of Action Immunomodulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Research Hepatitis B; Hepatitis C
  • Discontinued Immunological disorders

Most Recent Events

  • 28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International
  • 16 Jul 2009 ViRexx receives grant from the National Research Council of Canada for vaccine development in hepatitis B and hepatitis C
  • 16 Jul 2009 Early research in Hepatitis B in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top